
Heart & Vascular Disease Prevention
On this page
The UCSF Center for Prevention of Heart and Vascular Disease cares for patients with heart and blood vessel conditions as well as patients who may be at risk of developing them. Our comprehensive approach to anticipating and managing cardiovascular disease centers on attentive, personalized care.
First, you’ll undergo a thorough evaluation. Our specialists identify factors that may raise your chances of developing a cardiovascular condition or contribute to its progression. Depending on your needs, we may also provide:
- Consultations with a dietitian
- Medication assistance from a pharmacist
- Exercise stress testing (a way to assess heart function during exertion)
- Referral to an exercise physiologist
To make our care easier to access, our cardiologists offer telehealth video visits as well as in-person appointments.
Our team will meet you where you are, with the goal of helping you live a long, healthy life. We look forward to working with you.
The UCSF Center for Prevention of Heart and Vascular Disease cares for patients with heart and blood vessel conditions as well as patients who may be at risk of developing them. Our comprehensive approach to anticipating and managing cardiovascular disease centers on attentive, personalized care.
First, you’ll undergo a thorough evaluation. Our specialists identify factors that may raise your chances of developing a cardiovascular condition or contribute to its progression. Depending on your needs, we may also provide:
- Consultations with a dietitian
- Medication assistance from a pharmacist
- Exercise stress testing (a way to assess heart function during exertion)
- Referral to an exercise physiologist
To make our care easier to access, our cardiologists offer telehealth video visits as well as in-person appointments.
Our team will meet you where you are, with the goal of helping you live a long, healthy life. We look forward to working with you.
Conditions we treat
We see patients with a wide range of concerns, including:
- Coronary Artery Calcification
- Coronary Artery Disease
- Elevated Lipoprotein
- Family history of cardiac disease
- Hyperlipidemia
- Hypertension
- Hypertriglyceridemia
- Insulin Resistance
- Metabolic Abnormalities
- Metabolic Syndrome
- Obesity
- Peripheral Arterial Disease
- Prediabetes
- Women’s Heart Disease
Locations
Providers

Phoebe Ashley, MD
Cardiology
Ramzi Dudum, MD, MPH
Cardiology
Prerna Gupta, MD, MS
Cardiology
Julio A. Lamprea Montealegre, MD, PhD
Cardiology
Awards & recognition

Among the top hospitals in the nation

One of the nation's best for heart & vascular care
Related conditions & treatments
Conditions
- Abnormal Glucose Metabolism
- Cardiovascular Disease
- Coronary Artery Calcification
- Coronary Artery Disease
- Hyperlipidemia Syndrome
- Hypertriglyceridemia
- Hypertension
- Obesity
- Prediabetes
Treatments
- Advanced Cardiac Stress Test
Clinical trials
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Opens in a new window
Recruiting
Number of participants with Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), TEAEs of special interest, including...AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary LesionsOpens in a new window
Recruiting
Target Lesion Failure (TLF) rate - defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wav...FORWARD CAD IDE StudyOpens in a new window
Recruiting
Freedom from major adverse cardiac events (MACE) within 30 days of the index procedure. MACE (Clinical Events Committee [CEC] adjudicated) is defined as:...Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaOpens in a new window
Recruiting
Evaluate the effect of inclisiran compared to placebo on reducing LDL-C [percent change] at Day 330




